Loading...
•
Jun 30, 2021
Capricor Q2 2021 Earnings Report
Capricor reported financial results for the second quarter ended June 30, 2021 and provided a corporate update.
Key Takeaways
Capricor Therapeutics reported revenue of $200,000 and a net loss of $4.7 million, or $0.21 per share, for the three months ended June 30, 2021. The company's cash and cash equivalents balance totaled approximately $38.1 million as of June 30, 2021.
Completed an end-of-phase-II meeting with FDA and planning to move forward with start-up activities for a Phase III pivotal trial for CAP-1002 for the treatment of DMD.
Completed GLP toxicology study and are nearing completion of IND-enabling studies for multivalent exosome-mRNA vaccine candidate.
Signed exclusive, worldwide licensing agreement with Johns Hopkins University to include engineered exosomes for vaccines and therapeutics as part of the Company’s exosome technology portfolio.
Enrollment of INSPIRE clinical trial for treating severe COVID-19 patients increase with the emerging prevalence of the Delta variant.
Forward Guidance
Based on our current pipeline and operating plan, the Company’s cash position is expected to be sufficient to support operations for at least two years.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...